Thursday, July 22, 2021 During this on-camera webinar, strategic approaches and actionable tactics for building and improving RWE knowledge throughout your organization to help tap into new opportunities will be shared.
Register Free: http://www.pharmexec.com/pe_w/rwe
Event overview
Wondering how you can expand real world evidence (RWE) knowledge and buy-in in your Pharma or MedTech organization? Curious about how you can initiate increased innovation around RWE? Regardless of the size and scope of your organization, how can you help address these considerations and turn them into opportunities for innovation?
During this on-camera webinar, IQVIA experts will be joined by a current IQVIA customer to highlight strategic approaches and actionable tactics for building and improving RWE knowledge throughout your organization to help tap into new opportunities. Whether you work for an established organization or a growing one, there are different needs and often gaps that can be closed by taking the time to educate and train teams in an interactive and rewarding way. IQVIA’s Real World Academy On-Call is an effective resource to help you meet those needs.
The webinar will be of most interest to those in biopharma and medical device and diagnostics companies, with roles focused in RWE Centers of Excellence, HEOR, Medical Affairs, Epidemiology, Clinical Development, Market Access, and Brand.
We hope to see you on July 22! Can’t make it for the live presentation? Register and an on-demand recording will be sent to you following the webinar.
3 key takeaways
Chirag Ghai joined IQVIA in 2013 and is a senior leader on the Real World Evidence Solutions team. In his role, Chirag leads the development of RWE strategy and integrated evidence generation plans to maximize product value, from molecule to market in large and emerging biopharma organizations.
Previously, Chirag spent 10 years with the management consultancies Booz Allen Hamilton and Deloitte Consulting where he helped address the senior agenda for a variety of stakeholders in the healthcare industry, including biopharma, payers, and providers. Chirag earned an MBA with concentrations in healthcare strategy and finance from Case Western Reserve University in Cleveland, Ohio, and a B.A. (Honors) in Economics from Delhi University.
Nathalie Horowicz-Mehler, PhD
VP, Practice Lead, Real World Evidence Solutions
IQVIA
Nathalie is an epidemiologist by training with experience in health economics and outcomes research. Over the past 15 years, Nathalie has built a foundation in designing prospective observational studies incorporating survey research or including patient-reported outcomes development and validation, in retrospective chart reviews or database studies, and in health economic modeling using decision analytic techniques. To ensure that the evidence generated has the desired impact, Nathalie has been focused on developing evidence generation strategies to position assets for optimal market access.
Nathalie earned her B.S. in Behavioral Neurosciences with a concentration in Pharmacology from Louis Pasteur University, France. She also holds an M.S. in Pain Management, Education, and Policy from Tufts University School of Medicine, and a Ph.D. in Cancer Epidemiology from the Mailman School of Public Health, Columbia University.
Roberto Uehara
Vice President, Medical Affairs, Oncology in Emerging Markets
Pfizer
Roberto Uehara has served as the vice president, medical affairs, oncology in the emerging markets of Pfizer Biopharmaceutical since 2017. Roberto isa medical oncologist with clinical practice and academic experience in solid tumors, hematological malignancies, and bone marrow transplantation. He has 15 years of experience in different therapeutic areas within the pharmaceutical industry, and vast working experience at the country, regional, multi-regional, and global levels in developed and emerging countries.
Register Free: http://www.pharmexec.com/pe_w/rwe
Streamlining the Path to Market for Novel Therapies: 5 Strategies for Success
October 15th 2021While advanced therapy medicinal products (ATMPs) hold great promise, the path to exploiting the technology has been challenging. Christian K. Schneider outlines the five strategies that must be considered to increase the success rates of development programs, while avoiding some of the common pitfalls.